Welcome to our dedicated page for Azitra SEC filings (Ticker: AZTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Azitra Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on precision dermatology. Recent disclosures cover proxy materials for annual and special stockholder meetings, shareholder voting procedures, board and governance matters, and meeting-status updates filed on Form 8-K.
Azitra's SEC reports also describe material agreements and capital-structure changes, including private placement securities, Series A preferred stock and Series B and Series C warrants. Other filings address furnished financial results, pipeline business updates, use of financing proceeds for research and development and working capital, and NYSE American continued-listing compliance matters tied to stockholders' equity standards.
Azitra, Inc. reported Q1 2026 results showing higher operating investment and a stronger cash position while advancing its dermatology pipeline. Research and development expenses were $1.6 million versus $1.3 million a year earlier, and general and administrative expenses were $2.4 million versus $1.9 million. Net loss was $3.9 million compared with $3.1 million in Q1 2025, reflecting increased spending to support programs.
As of March 31, 2026, Azitra held $10.1 million in cash and cash equivalents, up from $2.1 million at year-end 2025, and total assets were $12.1 million. The company highlighted clinical progress for ATR-12 in Netherton syndrome, ATR-04 for EGFR inhibitor–associated rash, ATR-01 in ichthyosis vulgaris, and a new ATR-COSF cosmeceutical initiative targeting cosmetic applications, supported by a previously priced private placement of up to approximately $10.5 million with additional potential warrant proceeds.
Azitra, Inc. reported a net loss of $3.9 million for the quarter ended March 31, 2026, compared with $3.1 million a year earlier, as it continues pre‑revenue development of precision dermatology therapies.
Cash and cash equivalents rose to $10.1 million from $2.1 million at December 31, 2025, mainly from a $10.4 million Series A preferred financing and draws on an equity line of credit. Stockholders’ equity increased to $10.5 million, but the company has an accumulated deficit of about $72.4 million and used $2.5 million of cash in operating activities this quarter.
Management states there is substantial doubt about the company’s ability to continue as a going concern over the next twelve months without additional financing. Azitra also remains subject to NYSE American continued listing requirements after previously receiving a deficiency notice, and is relying on equity offerings, an equity line of credit with up to $20 million capacity, and newly issued Series A preferred stock and large warrant packages that could convert into or be exercisable for hundreds of millions of common shares.
Azitra, Inc. is asking stockholders at its virtual June 4, 2026 annual meeting to approve several major capital structure changes and routine governance items. Stockholders will elect four directors, including CEO Francisco D. Salva and COO Travis Whitfill, and vote on ratifying Grassi & Co., CPAs, P.C. as auditor for 2026.
The company seeks to amend its charter to increase authorized common stock from 200,000,000 to 750,000,000 shares, citing forecasted capital-raising needs to fund product development and other uses. As of April 24, 2026, 16,192,438 shares of common stock were outstanding, with a very large number of additional shares reserved, primarily for warrants.
Azitra also requests authority for the Board to implement one or more reverse stock splits at a ratio between 1-for-2 and 1-for-30 to help support compliance with NYSE American listing requirements. Additional proposals seek NYSE American–required approval for potential issuances of more than 19.99% of outstanding shares under a 2025 Alumni Capital LP agreement and a March 18, 2026 financing involving Series A Preferred Stock and Series B and C Warrants, plus an amendment and restatement of the 2023 Stock Incentive Plan to increase its share reserve and permission to adjourn the meeting if more votes are needed.
Azitra, Inc. is soliciting proxies for its 2026 Annual Meeting to be held virtually on June 4, 2026. The proxy seeks approval for nine proposals, including an amendment to increase authorized common shares from 200,000,000 to 750,000,000, shareholder authorization enabling the Board to effect one or more reverse stock splits at ratios between 1-for-2 and 1-for-30, approval related to issuances exceeding 19.99% under two recent securities purchase agreements, an amendment to increase the 2023 Stock Incentive Plan reserve, election of four directors, and ratification of the independent auditor. Shares outstanding were 16,192,438 as of April 24, 2026.
Azitra, Inc. Chief Financial Officer Norm Staskey received a grant of 35,524 stock options to buy common shares. The options have an exercise price of $0.2127 per share and expire on April 20, 2036. After this grant, Staskey holds 35,524 options directly.
One third of the options will vest on the one-year anniversary of the grant date, and the remaining two thirds will vest in equal monthly installments over the following two years. This is a compensation-related award rather than an open-market purchase or sale.
Azitra, Inc. reported that President and CEO Francisco D. Salva received a grant of stock options covering 220,879 shares of common stock. The options have an exercise price of $0.2127 per share and expire on April 20, 2036.
According to the vesting terms, one-third of the options vest on the one-year anniversary of the grant date, and the remaining two-thirds vest in equal monthly installments over the following two years. After this grant, Salva directly holds options for 220,879 underlying shares.
Azitra, Inc. reported that Chief Operating Officer Travis Whitfill received a grant of stock options covering 64,300 shares of common stock. The options carry an exercise price of $0.2127 per share and expire on April 20, 2036.
According to the vesting terms, one-third of the options will vest on the one-year anniversary of the grant date, and the remaining two-thirds will vest in equal monthly installments over the following two years. After this grant, Whitfill holds 64,300 stock options directly.
Azitra, Inc. has completed a private PIPE financing that can provide up to approximately $31.4 million, including initial gross proceeds of about $10.5 million from the sale of 10,485 shares of Series A convertible non-redeemable preferred stock bundled with warrants.
Each preferred share is paired with Series B and Series C warrants, each initially exercisable at $0.123 per share. After stockholder approval of additional authorized common shares and the related NYSE American requirements, each preferred share will automatically convert into roughly 8,128.1 common shares, subject to beneficial ownership caps of 4.99%, 9.99% or 19.99% per holder, with excess delivered as pre-funded warrants.
The Series B warrants become exercisable after stockholder approval and terminate 18 months later, while Series C warrants remain exercisable until 30 days after Azitra publicly reports data from its cosmetic filaggrin human study, with a potential 30-day extension and exercise price reset if the stock trades below the original strike. A registration rights agreement requires Azitra to file a resale registration statement within 45 days of closing, with liquidated damages of 1% of each investor’s purchase amount per 30 days if key registration milestones are missed. Azitra plans to use the initial net proceeds, together with existing cash, for research and development, general corporate purposes and working capital.
Azitra, Inc. President and CEO Francisco D. Salva reported significant insider purchases of derivative securities. On March 18, 2026, he bought 500 shares of Series A Convertible Non-Redeemable Preferred Stock, which has a stated value of $1,000 per share and automatically converts into 8,128.1 shares of common stock per preferred share once specific stockholder approvals and a charter amendment are obtained.
He also purchased 4,064,050 Series B Warrants and 4,064,050 Series C Warrants, each exercisable for common stock at $0.123 per share. The Series B Warrants become exercisable upon stockholder approval and expire 18 months afterward, while the Series C Warrants become exercisable upon stockholder approval and terminate 30 days after Azitra publicly announces data from its planned human cosmetic study using filaggrin technology.